IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients
- PMID: 7585729
IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients
Abstract
The aim of this review was to compare the clinical characteristics and prognostic factors of Japanese and Western IgD myeloma patients, and also to introduce our new staging system, based on the analysis of Japanese patients. We reviewed 165 Japanese with IgD myeloma reported since the first Japanese case report in 1967 and compared these patients with Western IgD myeloma patients reported in the literature. Parameters evaluated were recorded at diagnosis. The staging systems of Durie and Salmon and the British Medical Research Council (BMRC) were also applied to our series. Survival curves were calculated according to the method of Kaplan & Meier and generalized Wilcoxon test and log-rank test were used to assess differences in survival. Multivariate analysis was performed by the Cox proportional hazard model. We were able to confirm the similarity of clinical features in Japanese patients and those reported in Western countries. We did, however, find small differences in the incidence of lymphadenopathy, thrombocytopenia, and high serum levels of creatinine, and in the 5-year survival rates. Assessment of prognostic factors influencing survival was compared in Japanese and Western patients. A multiple regression model in our series showed that light chain subtype and leukocyte count had a strong predictive relationship for duration of survival. A new risk grouping using these two major factors was introduced since neither the common staging system of Durie & Salmon nor those of the BMRC predicted survival in these patients; to date, there are still no reports from Western countries in this regard.
Similar articles
-
Prognostic factors and staging systems of multiple myeloma:Chin Med J (Engl). 2007 Oct 5;120(19):1655-8. Chin Med J (Engl). 2007. PMID: 17935664
-
International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.Neoplasma. 2006;53(4):277-84. Neoplasma. 2006. PMID: 16830053
-
[Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].Ai Zheng. 2006 Apr;25(4):461-4. Ai Zheng. 2006. PMID: 16613681 Chinese.
-
[Prognostic factors of multiple myeloma].Ann Med Interne (Paris). 1997;148(8):534-41. Ann Med Interne (Paris). 1997. PMID: 9538400 Review. French.
-
A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.Cancer. 2003 May 15;97(10):2440-52. doi: 10.1002/cncr.11072. Cancer. 2003. PMID: 12733143 Review.
Cited by
-
Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma.BMC Cancer. 2018 Jun 11;18(1):650. doi: 10.1186/s12885-018-4562-8. BMC Cancer. 2018. PMID: 29890944 Free PMC article.
-
A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.J Exp Clin Cancer Res. 2022 Mar 8;41(1):85. doi: 10.1186/s13046-022-02276-7. J Exp Clin Cancer Res. 2022. PMID: 35260179 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical